Mono PharmacareNSE:MONOPHARMA -1.79%9 Median PS Value is ₹0.00 as of Jul. 08, 2026. GuruFocus rates NSE:MONOPHARMA with a GF Score™ of 9/100. The stock has 6 warning signs investors should review. Among 263 Healthcare Providers & Services companies, Mono Pharmacare ranks worse than 380227.76% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
As of today (2026-07-08), Mono Pharmacare's share price is ₹11.00. Mono Pharmacare's Median PS Value is ₹0.00. Therefore, Mono Pharmacare's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for Mono Pharmacare's Median PS Value or its related term are showing as below:
NSE:MONOPHARMA's Price-to-Median-PS-Value is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 0.7 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
Mono Pharmacare (NSE:MONOPHARMA) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Mono Pharmacare's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
11.00
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mono Pharmacare Median PS Value Related Terms
Mono Pharmacare Median PS Value Historical Data
* Premium members only.
The historical data trend for Mono Pharmacare's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mono Pharmacare Median PS Value Competitor Comparison
For the Pharmaceutical Retailers subindustry, Mono Pharmacare's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mono Pharmacare Price-to-Median-PS-Value vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Mono Pharmacare's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Mono Pharmacare's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Mono Pharmacare's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2025 was ₹78.205.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mono Pharmacare (NSE:MONOPHARMA) has a Median PS Value of ₹0.00 as of Jul. 08, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Mono Pharmacare and its competitors. According to the industry distribution chart, Mono Pharmacare ranks #999999 out of 263 companies in the Healthcare Providers & Services industry.
Is Mono Pharmacare's Median PS Value too high?
Mono Pharmacare's current Median PS Value is ₹0.00. Based on the distribution chart, Mono Pharmacare ranks #999999 out of 263 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Mono Pharmacare has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Mono Pharmacare's Median PS Value compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Mono Pharmacare ranks #999999 out of 263 companies for Median PS Value. This places Mono Pharmacare in the lower half of its industry. The industry median Median PS Value is 0.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Healthcare Providers & Services company?
The median Median PS Value among Healthcare Providers & Services companies is 0.70, based on 263 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Mono Pharmacare and its competitors. For the Healthcare Providers & Services industry, the median Median PS Value is 0.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mono Pharmacare's current Median PS Value is ₹0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mono Pharmacare stock overvalued right now?
Mono Pharmacare (NSE:MONOPHARMA) has a current Median PS Value of ₹0.00. The current Median PS Value is ₹0.00. Mono Pharmacare's overall GF Score™ is 9/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Mono Pharmacare (NSE:MONOPHARMA), the current Median PS Value is ₹0.00 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Mono Pharmacare Ltd distributes a broad range of pharmaceutical products across India. Its portfolio includes antibiotics, antifungal medicines, cough and cold remedies, antacids, analgesics, nutraceuticals, skincare, antiseptics, cardiac and diabetic drugs, and cosmetic items. The company operates through contract manufacturing, sourcing products from various manufacturers and supplying them to healthcare providers and pharmacies. Revenue is generated through the sales and distribution of these pharmaceutical and healthcare products in the Indian market.
9GF Score
Get the complete analysis for NSE:MONOPHARMA
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MONOPHARMA has been successfully added to your 
